Picture loading failed.

Anti-CD3E;MS4A1 therapeutic antibody (Pre-made Glofitamab biosimilar,Bispecific mAb with Domain Crossover) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).



Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-248-1mg 1mg Inquiry
GMP-Bios-ab-248-10mg 10mg Inquiry
GMP-Bios-ab-248-100mg 100mg Inquiry
GMP-Bios-ab-248-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD3E;MS4A1 therapeutic antibody (Pre-made Glofitamab biosimilar,Bispecific mAb with Domain Crossover)
INN Name Glofitamab
TargetCD3E;MS4A1
FormatBispecific mAb with Domain Crossover
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda;Kappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone;3pp3:HL/3pp4:HL
99% SI StructureNone;6y9a:HL
95-98% SI StructureNone;6y97:HL
Year Proposed2019
Year Recommended2020
CompaniesRoche
Conditions Approvedna
Conditions ActiveDiffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma
Conditions Discontinuedna
Development Techna